NCT01015027View on ClinicalTrials.gov

Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Healthy
Interventions
BIOLOGICAL

REGN668

4 IV Cohorts (Dose 1, 2, 3, \& 4)

Trial Locations (1)

Unknown

Baltimore

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY